Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
UK |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ADAP's stock price target?
Not Available
ADAP doesn't have any price targets made by Wall Street professionals.
What is Adaptimmune Therapeutics PLC's Revenue forecast?
Projected CAGR
9%
For the last 11 years the
compound annual growth rate for
Adaptimmune Therapeutics PLC's revenue is
68%.
The projected
CAGR
for the next 4 years is
9%.